Your email address will not be published. Required fields are marked *
Invenio Medical Inc. is in the final stages of research and development of the AptaSure MRSATM test kit. The Standard Operating Procedures (SOPs), and technology transfers, are being prepared by our Research & Development (R&D) team. We have recently commenced interviewing Manufacturers for production of the product. Once we have completed these interviews, with the ultimate selection of a desired Manufacturer, we will build our first product batch for a LIVE test phase at several, highly regarded, University Medical Centers throughout the country. We anticipate the test phase to rapidly demonstrate what we have learned at the bench. This includes high sensitivity, high specificity, and rapid identification of MRSA, which will provide significantly higher quality of care to patients, and reduction in attributable hospital costs. We look forward to hearing from the feedback that these elite hospitals will provide us. Once these milestones are accomplished, we will begin marketing, and selling the AptaSure MRSATM to hospitals, from coast to coast. We anticipate a healthy return. Again, we thank you for your trust as we move into these final R&D stages. It is not often that simple investors are able to partake in a “revolutionary” product such as AptaSure MRSATM. We will only continue to move forward with great strides, thereby increasing the valuation of our company.
Invenio Medical, Inc. Board of Directors
Invenio Medical, Inc. Continues to make amazing progress in Research & Development of our AptaSureTM MRSA device. Over the past 3 months, we have conducted thousands of tests on our product, including the use of live MRSA bacteria, with outstanding results. We are seeing improved sensitivity and specificity, resulting in a significant reduction of false positives/negatives over current state of the art technology. We have also seen that our product will have an increased shelf life beyond 1 year, approaching 2 years. Our research team continues to develop the optimal recipe of aptamer, monoclonal antibody, utilizing the best detergents and buffers. Every day, we near the final process of our product R&D, along with upcoming discussions with manufacturing entities. We are still on track for product delivery to the market-place sometime in the 3rd quarter of 2018. We appreciate your faith in our research team and officers as we continue to develop a medical device which has been described by one of our research scientists as a “REVOLUTIONARY” product.
The Invenio-Medical, Inc. Team
The following information has been provided to us by both of our research scientists who are developing our AptaSure MRSA device.
Dr. Yongsheng Shi, PhD, MD: UCI – College of Medicine, Department of Molecular Biology and Genomics
Invenio Medical, Inc. is in the process of developing a new lateral flow strip assay (LFSA) utilizing aptamers functionalized with gold nanoparticles (AuNP). This new LFSA biosensor utilizes a cognate aptamer duo binding to pbp2a, a target protein, at 2 different binding sites, exhibiting a sensitive and highly selective response. Our studies have shown successful development of a single yet effective LFSA for pbp2a detection without any special laborious instrumentations. This system will be particularly useful as a screening tool for rapid, on-site detection of any targets with a pair of aptamers generated.
Immobilize the various AuNP biosensors into plastic – injection molded holders for allowance to incorporate design into products that will be supplied to Dr. Bohannon for further optimization of the system that he is currently testing. Our designers are currently obtaining various siliconized plastics for infusion into plastic injection.
23/01/2018 – News
Dr. Robert Bohannon, PhD: Catalloid Products, Inc.
We have come a long way in a short time. We look towards our future, knowing that we have the very best scientists working with us to bring a state of the art medical device to the forefront of rapid infectious disease diagnostics. We strive to fulfill our desire of becoming THE “tool” that healthcare providers will insist upon for enhancing patient safety to the highest levels possible.
The Invenio Medical Team
Many of you have either called, sent text messages, or emailed me, regarding our website and investor page. You have most likely also obtained the generic password, and noticed the updated information on the status of our company. This page is the current information for your review and consideration.
We at Invenio Medical Inc. want to thank you, our Investors, very much. There are MANY individuals who unfortunately did NOT have the opportunity to purchase stock in Phase 1, and there were also many of you who did purchase initial stock, and came back, wanting to purchase more. Hold those thoughts and capital. In the interest of keeping the valuation of stock from being damaged, and the subsequent need for additional Phase 2 funding to be secure, you will soon have the opportunity to become an investor in this exciting company.
Phase 1 Financing stock sale has successfully come to a conclusion (penny stock). We are happy to report we have reached our funding goals as stated in the business plan. We thank all investors who participated. There WILL be a Phase 2 sometime in 2018. The sale of shares WILL be at a higher cost to investors (undetermined), but still a tremendous potential for those who wish to participate.
As mentioned previously both prototype and optimization of AptaSure™ devices are concurrently in development. We will report the status of this process after the New Year. We are encouraged that to date, there have been no unresolved issues identified, and the process is on track and going smoothly.
Our CEO, Dr. Lange, and CFO Kevin Ohler, have engaged in final negotiations with our aptamer provider to secure licensing and provide Invenio Medical, Inc. the protection for our AptaSure™ devices from competition. We hope to have this completed soon after the New Year as well.
Dr. Lange has reached out to the USPTO to understand the timing of our application for patent protection. He was told the number of patents applied for has increased nearly 5 fold and the process is ongoing, and will be completed, but a time line is just not available at this time.
Once again, we are honored to have you as part of our investor team. After all, you will be part of the evolution of a groundbreaking medical device that will revolutionize the way by which Infectious Diseases are screened for and identified.
On behalf of Invenio Medical, Inc. , we wish you and your families a very Happy & Healthy Holiday Season!
Jay Haischer, MHA, RPA-RT, VA-BC
Chief Operations Officer
951-956-3561 – Mobile
951-845-5075 – Home Office / Fax
877-688-8829 – Corporate Office
www.invenio-medical.com – Web
Invenio Medical, Inc.’s vision is to research, design and develop, groundbreaking medical technologies/devices, increasing provider efficiency, while providing thehighest level of patient safety.
Invenio Medical, Inc. recognizes the challenges of modern healthcare. Our research and development team consists of experts from around the world. We are fortunate to have retained leading pioneers in research and development, who have developed numerous groundbreaking technologies within the healthcare sector. Most of these devices had been developed for use in hospitals, clinics, nursing homes, as well as physician office settings.
Invenio Medical, Inc. has entered into agreements with several highly regarded research laboratories, to develop and optimize our AptaSure™ product line. First, the University of California – Irvine, Medical College, Department of Microbiology and Genomics, has agreed to assist in the development and rapid-prototyping of our AptaSure™ MRSA product. This particular laboratory is led by Dr. Yongsheng Shi, PhD a highly skilled professor, and researcher, who has committed the time and resources available to bring our prototype to a reality in a relatively rapid time frame. The majority of his work is conducted via National Institute of Health (NIH) grants. His personal interest in our project, of aiding humankind with our AptaSure™ devices, has provided Invenio Medical, Inc. with an incredible opportunity for to partner with such a remarkable industry expert. Dr. Shi is acknowledged and credentialed by The American Cancer Society for his research and work. We are honored to have Dr. Shi as part of our remarkable research and development team, providing his knowledge, clinical skills and expertise, along with his Doctoral student lab assistants, helping us reach our ultimate goal, of providing state of the art, low cost, rapid diagnostics to patients worldwide.
Dr. Robert Bohannon, PhD. is another valuable member of our Research and Development team. Dr. Bohannon is President of Catalloid Products, Inc., On Site Testing Labs, Inc., as well as Chief Scientific Officer for EKF Life Sciences and Diagnostic Company. Bob obtained his PhD from Baylor College of Medicine in Molecular Virology. He holds degrees from the University of Colorado in Molecular Biology and a degree in Organic Chemistry from The University of California at Berkley. Dr. Bohannon helped develop lateral flow, EIA and molecular tests for various diagnostic companies worldwide. He developed a novel POC oral cancer screening test as well as avian flu, HPV, Strep A/B and drugs of abuse. He oversaw development of lateral flow tests for anthrax, ricin, botulism toxin and agents for First Responders. He has been called a first rate scientist with a flair for developing cutting edge technologies to solve practical problems by his fellow researchers. He calls himself an innovator, visionary and creative guru. We call him the PREMIER scientist in the field. He is an out-of-the-box thinker, a true genius in every regard. We are honored to have such an amazing scientist as Dr. Robert Bohannon, PhD, working with us on our project.
As you can see, Invenio Medical, Inc. will go above and beyond, to partner with outstanding research and development scientists, ultimately ensuring that the investment you have made in our company, has the greatest potential for success in the healthcare marketplace. We thank you for your investment, and we will strive daily to ensure that your investments reach maximum potential in the shortest timeframe possible.